US Patent

US8080537 — Combinations of adapalene and benzoyl peroxide for treating acne lesions

Method of Use · Assigned to Galderma Research and Development SNC · Expires 2027-07-18 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of adapalene in combination with benzoyl peroxide for reducing the number of acne lesions through daily topical application.

USPTO Abstract

Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.

Drugs covered by this patent

Differin (ADAPALENE) · Galderma Labs Lp

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1078`	—	Differin

Patent Metadata

Patent number: US8080537
Jurisdiction: US
Classification: Method of Use
Expires: 2027-07-18
Drug substance claim: No
Drug product claim: No
Assignee: Galderma Research and Development SNC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.